CTOs on the Move

Velsera

www.velsera.com

 
Velsera is a company that connects healthcare and life sciences to reveal the true promise of precision medicine. They power this ecosystem of insight with data made actionable by AI and technology solutions that accelerate R&D, democratize omics and p...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

AgriThority

AgriThority® is the first independent data-through-delivery product and market development company in the agriculture industry. Instead of delivering a “data dump” and walking away, AgriThority® assimilates and summarizes data to ensure you get the consistency and continuity your project demands. Producers benefit, too. AgriThority® has unmatched strength in the development of best management practices (BMPs) in animal health, agronomic and horticultural crop production, and in the development of product use within those BMPs. AgriThority® further builds trust and credibility for products and innovations by providing and delivering training and educational programs for company sales and field development organizations, technical influencers, channel partners and producers.

NextBio

NextBio is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Board of Nuclear Medicine

American Board of Nuclear Medicine is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regenacy Pharmaceuticals

Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function.

Pyxis Oncology

Founded by Longwood Fund, Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis is employing site-specific conjugation technology to develop highly stable ADCs with enhanced therapeutic indexes. Pyxis is also advancing a diverse portfolio of immunotherapies that target broad immune regulators as well as novel immune checkpoints identified through its immuno-oncology and cold tumor discovery efforts.